Niu Yishan, Yuan Xiaoye, Guo Fansheng, Cao Jinglin, Wang Yang, Zhao Xin, Dou Jian, Zeng Qiang
Department of Hepatobiliary Surgery, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, 050051, People's Republic of China.
Department of Gerontology, Hebei General Hospital, Shijiazhuang, Hebei, 050051, People's Republic of China.
Int J Gen Med. 2024 May 27;17:2445-2453. doi: 10.2147/IJGM.S450585. eCollection 2024.
This investigation evaluated the prognostic significance of the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), and introduced a combined NLR-PLR score to evaluate the correlation between NLR-PLR score and hepatocellular carcinoma (HCC) recurrence.
MATERIAL/METHODS: We enrolled 110 patients who underwent orthotopic liver transplantation (LT) for HCC. The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were assessed, and appropriate cut-off values were established. The NLR-PLR score ranged from 0 to 2 as follows: score of 2, high NLR (≥3.37) and high PLR (≥105.96); score of 1, either high NLR or high PLR; score of 0, neither high NLR nor high PLR.
The median overall survival (OS) of patients with NLR-PLR score of 0, 1 and 2 was 27, 26.5, and 6 months, respectively. The median OS of patients with NLR-PLR score of 2 was shorter than those with 0 ( < 0.001) and 1 ( < 0.001). The median disease-free survival (DFS) time of patients with NLR-PLR score of 0, 1 and 2 was 24.5, 24, and 6 months, The median DFS of patients with NLR-PLR score of 2 was shorter than those with 0 ( = 0.001) and 1 ( = 0.015). Multivariate analysis showed that NLR-PLR score was an independent risk factor for prognosis and survival.
NLR, PLR and NLR-PLR score can predict the long-term survival of patients, and NLR-PLR score, having more predictive value than NLR and PLR alone is an independent risk factor for patient survival. more predictive value than NLR and PLR alone.
本研究评估了中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）的预后意义，并引入了NLR - PLR联合评分来评估NLR - PLR评分与肝细胞癌（HCC）复发之间的相关性。
材料/方法：我们纳入了110例因HCC接受原位肝移植（LT）的患者。评估了中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR），并确定了合适的临界值。NLR - PLR评分范围为0至2，如下：2分，高NLR（≥3.37）且高PLR（≥105.96）；1分，高NLR或高PLR；0分，既非高NLR也非高PLR。
NLR - PLR评分为0、1和2的患者的中位总生存期（OS）分别为27个月、26.5个月和6个月。NLR - PLR评分为2的患者中位OS短于评分为0（<0.001）和1（<0.001）的患者。NLR - PLR评分为0、1和2的患者的无病生存期（DFS）中位数分别为24.5个月、24个月和6个月。NLR - PLR评分为2的患者中位DFS短于评分为0（=0.001）和1（=0.015）的患者。多因素分析表明，NLR - PLR评分是预后和生存的独立危险因素。
NLR、PLR和NLR - PLR评分可预测患者的长期生存，且NLR - PLR评分比单独的NLR和PLR具有更高的预测价值，是患者生存的独立危险因素。比单独的NLR和PLR具有更高的预测价值。
